Kura Oncology, Inc.
KURADrugs in Pipeline
3
Phase 3 Programs
1
Upcoming Catalysts
1
Next Catalyst
Next month
Market Overview
Stock performance and key metrics
1 upcoming, 0 past
How KURA's past catalysts played out
Ziftomenib
Acute Myeloid Leukemia (AML)
Tipifarnib
HNSCC
Midazolam
Advanced Malignant Neoplasm
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Ziftomenib | Phase 3 | Acute Myeloid Leukemia (AML) | - | - |
Tipifarnib | Phase 2 | HNSCC | - | - |
Midazolam | Phase 2 | Advanced Malignant Neoplasm | - | - |
Advanced Malignant Neoplasm
1 drug in this indication
HNSCC
1 drug in this indication
Acute Myeloid Leukemia (AML)
1 drug in this indication
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in Kura Oncology, Inc.'s drug pipeline?→
CatalystAlert tracks 3 drug candidates in Kura Oncology, Inc.'s (KURA) pipeline across Phase 3, Phase 2. Its lead program is Ziftomenib (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Kura Oncology, Inc.'s next FDA catalyst?→
Kura Oncology, Inc.'s (KURA) next tracked catalyst is a Earnings expected November 3, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track KURA biotech catalysts?→
Add KURA to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Kura Oncology, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.